From: High HSPB1 expression predicts poor clinical outcomes and correlates with breast cancer metastasis
Characteristics | Total(N) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
Age | 2765 | Â | Â | Â | Â |
 <  = 60 | 1382 | Reference |  |  |  |
 > 60 | 1383 | 1.152 (0.831–1.625) | 0.273 |  |  |
T stage | 2759 | Â | Â | Â | Â |
T1 | 573 | Reference | Â | Â | Â |
T2&T3&T4 | 2186 | 1.974 (1.164–2.977) | 0.004 | 1.527 (0.822–2.312) | 0.313 |
N stage | 2753 | Â | Â | Â | Â |
N0 | 1374 | Reference | Â | Â | Â |
N1&N2&N3 | 1378 | 2.712 (1.742–3.529) |  < 0.001 | 1.631 (1.042–2.636) | 0.034 |
M stage | 2649 | Â | Â | Â | Â |
M0 | 1913 | Reference | Â | Â | Â |
M1 | 736 | 7.137 (3.785–12.465) |  < 0.001 | 5.024 (3.607–10.143) |  < 0.001 |
Pathologic stage | 2746 | Â | Â | Â | Â |
Stage I | 381 | Reference | Â | Â | Â |
Stage II&Stage III&Stage IV | 2365 | 3.539 (1.613–5.746) | 0.013 | 1.463 (0.607–2.594) | 0.815 |
ER status | 2731 | Â | Â | Â | Â |
Negative | 643 | Reference | Â | Â | Â |
Positive | 2088 | 0.703 (0.342–1.327) | 0.019 | 0.820 (0.492–1.393) | 0.314 |
PR status | 2716 | Â | Â | Â | Â |
Negative | 721 | Reference | Â | Â | Â |
Positive | 1995 | 0.524 (0.311–0.816) |  < 0.001 | 0.573 (0.249–1.214) | 0.073 |
HER2 status | 1843 | Â | Â | Â | Â |
Negative | 1449 | Reference | Â | Â | Â |
Positive | 394 | 1.304 (0.801–2.024) | 0.526 |  |  |
radiation_therapy | 2679 | Â | Â | Â | Â |
No | 1163 | Reference | Â | Â | Â |
Yes | 1516 | 0.649 (0.434–1.407) | 0.434 |  |  |
HSPB1 | 2765 | Â | Â | Â | Â |
Low | 1382 | Reference | Â | Â | Â |
High | 1383 | 1.614 (1.307–1.942) | 0.045 |  |  |